JAGSNPHARM vs RELIANCE
Head-to-head DCF comparison · JAGSONPAL PHARMACEUTICALS vs Reliance Industries
Model Favors
JAGSNPHARM shows a larger model margin of safety
Leads on 3 of 4model metrics · not investment advice
JAGSNPHARM
JAGSONPAL PHARMACEUTICALS
General/Diversified
₹197
Fairly ValuedRELIANCE
Reliance Industries
Oil & Gas
₹1,343
Fairly Valued| Metric | JAGSNPHARM | RELIANCE |
|---|---|---|
| Verdict | Fairly Valued | Fairly Valued |
| YieldIQ Score | 61/100 | 30/100 |
| Fair Value | ₹184 | ₹1,266 |
| Current Price | ₹197 | ₹1,343 |
| Margin of Safety | -6.1% | -5.8% |
| Moat | Wide | Moderate |
| Piotroski F-Score | 8/9 | 6/9 |
| ROE | — | 6.9% |
| Debt / Equity | 0.03 | — |
| EV / EBITDA | 19.8× | 14.3× |
| Market Cap | ₹1,319 Cr | ₹18.18 Lakh Cr |
Run the full interactive analysis
DCF sliders, sensitivity tables, peer screens, watchlists — free to start.
Sign up free →Model estimates using publicly available data. Not investment advice. YieldIQ is not registered with SEBI as an investment adviser or research analyst.